

# COVID VACCINE INFORMATION FOR PHARMACIES

October 22<sup>nd</sup>, 2020

1

## PHARMACIST IMPACT

More than 25% of annual influenza vaccinations are administered within pharmacies

More than 50% of shingles vaccines are administered by pharmacists.




<https://pubmed.ncbi.nlm.nih.gov/28781217/>

2

# Coronavirus Vaccine Tracker

By Jonathan Corum, Sui-Lee Wee and Carl Zimmer Updated October 3, 2020



Current as of:  
October 7<sup>th</sup>, 2020

<https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html>

3

	Technology platform	U.S. government funding or advance commitment	Number of contracted or optioned doses	Dosage	Current Clinical Trial Phase	Storage
<b>AstraZeneca</b>	nonreplicating adenovirus vector	\$1.2 Billion	300 million	Two shots	Phase 3 (8/31)	Refrigerated
<b>Johnson &amp; Johnson</b>	nonreplicating adenovirus vector	\$456 million in early R&D funding, additional \$1 billion for doses if approved	100 million, option for 200 million more	Testing one and two shot regimens	Phase 3 (9/23)	Refrigerated
<b>Moderna</b>	mRNA	\$955M in R&D funding, up to \$1.525 billion for delivery	100 million, option for 400 million more	Two shots	Phase 3 (07/27)	Ultra-cold
<b>Novavax</b>	adjuvanted recombinant protein subunit	\$1.6 Billion	100 million	Two shots	Phase 3 (9/24)	Refrigerated
<b>Pfizer/BioNTech</b>	mRNA	\$1.95 Billion if vaccine is approved	100 million, option for 500 million more	Two shots	Phase 2/3 (07/27)	Ultra-cold
<b>Sanofi/GSK</b>	adjuvanted recombinant protein subunit	\$2.1 Billion	100 million, option for 500 million more	Two shots	Phase 1/2 (9/3)	Refrigerated
<b>Merck/IAVI</b>	recombinant vesicular stomatitis virus	\$38 Million	Unable to find information	Unknown	Trials have not begun	Likely Ultra-cold (Same tech as Ebola Vaccine)


<https://www.bloomberg.com/opinion/articles/2020-08-17/warp-speed-s-covid-19-vaccine-push-lacks-a-key-ingredient-trust>; <https://www.wsj.com/articles/covid-19-vaccine-race-turns-deep-freezers-into-a-hot-commodity-11599217201>; [https://www.iavi.org/phocadownload/iavi\\_fact\\_sheet\\_coronavirus-vaccine-program.pdf](https://www.iavi.org/phocadownload/iavi_fact_sheet_coronavirus-vaccine-program.pdf)

4

## POTENTIAL LOGISTICS CHALLENGES

- Limited vaccine availability initially
- Most vaccines require 2 doses, separated by 21 or 28 days.
- Vaccine products will NOT be interchangeable
  - Schedule follow up appointments
  - Provide vaccine record cards
  - Educate patients about VaxView
- Vaccine storage temperatures
- Reporting requirements

5



\*Planning should consider that there may be initial age restrictions for vaccine products.

\*\*See Section 4: Critical Populations for information on Phase 1 subset and other critical population groups.

6

## Looking Up Immunization History

### VaxViewNM.org


Allows patients, parents, and guardians to look up their vaccine records

Easy to use

Requires access to a computer or smartphone

Flyers available at:

<https://www.nmhealth.org/publication/view/marketing/5214/>



**VaxViewNM.org**

Did you know?  
Getting your child's shot record—or your record—from the State of New Mexico has never been easier!

Simply go to **VaxViewNM.org**

Here is the information you'll need:

- Patient's name—your child's name or your name
- Date of birth
- Cell phone number or email address

If you are unable to access your immunization record, contact your provider, your local public health office, or call NMSIS help desk at 1-833-882-6454

**new** You can now print your child's shot record at VaxViewNM.org

The security and protection of patient records is our highest priority. VaxViewNM uses two-factor authentication via text messaging or email to validate patient, parent, or guardian access. If you are not able to access your record, please contact your primary health provider to verify your contact information. VaxViewNM is a free service provided by the New Mexico Department of Health Immunization Program.

**NEW MEXICO DEPARTMENT OF HEALTH**

7

## Looking Up Immunization History

Consider registering all pharmacists and/or pharmacy technicians as NMSIS users so that they may utilize immunization history functions.

Chains may give read-only access



**New Mexico State Immunization Information System - NMSIS**

Login

Username

Password


[Forgot Password?](#)

8

### New Lows

Some of the vaccines being developed for Covid-19 might require colder temperatures for transport than typical vaccines.

A comparison, in degrees Celsius:



<https://www.wsj.com/articles/covid-19-vaccine-race-turns-deep-freezers-into-a-hot-commodity-11599217201>

## Do I need to prepare for Ultra-Cold Chain Vaccines?

- If multiple vaccines are available, retail pharmacies will receive only vaccines with conventional storage requirements
- Hospital pharmacies are more likely to receive ultra-cold vaccine
- The CDC is preparing logistics strategies in the case that there is only an ultra-cold chain vaccine approved

9

## Scenarios the CDC has Presented as Planning Exercises

### Availability Assumptions

Candidate	Vaccine availability under EUA by			Notes
	End of Oct 2020	End of Nov 2020	End of Dec 2020	
Vaccine A	~2 million (M) doses	10M–20M doses	20M–30M doses	Ultra-cold (-70 °C) storage requirements, for large sites only

### Distribution, Storage, Handling, and Administration Assumptions

Vaccine A	
<b>SHIPMENT</b> 3 separately acquired components (mixed on site) <ol style="list-style-type: none"> <li>Vaccine               <ul style="list-style-type: none"> <li>Direct to site from manufacturer (on dry ice)</li> <li>Multidose vials (5 doses/vial)</li> </ul> </li> <li>Diluent               <ul style="list-style-type: none"> <li>Direct to site from the US Government (USG) at room temperature</li> </ul> </li> <li>Ancillary supply kits (for administration and mixing)               <ul style="list-style-type: none"> <li>Direct to site from USG (at room temperature)</li> </ul> </li> </ol>	<b>ON-SITE VACCINE STORAGE</b> Frozen (-70 °C ± 10 °C) <ul style="list-style-type: none"> <li>Must be used/recharged within 10 days</li> <li>Storage in shipping container OK (replenish dry ice within 24 hours of receiving shipment and again 5 days later)</li> </ul> Thawed but NOT reconstituted (2–8 °C) <ul style="list-style-type: none"> <li>Must use within 5 days (discard unused doses after 5 days)</li> </ul> Reconstituted (room temperature) <ul style="list-style-type: none"> <li>Must use within 6 hours (discard any unused, reconstituted vaccine after 6 hours)</li> </ul>
<b>ORDERS</b> Large quantities, to large administration sites only <ul style="list-style-type: none"> <li>Minimum order: ~1,000 doses</li> <li>Maximum order: ~5,000 doses</li> </ul>	<b>ADMINISTRATION</b> 2-dose series (21 days between doses) <ul style="list-style-type: none"> <li>On-site mixing required; reconstitute with diluent just prior to administration</li> <li>Administer by intramuscular (IM) injection</li> </ul>
<b>INITIAL POPULATIONS OF FOCUS AND ANTICIPATED VACCINE ADMINISTRATION SITES</b> Healthcare personnel — public health, closed point of dispensing (POD), temporary/off-site vaccination clinics + potential for mobile clinics Other essential workers — public health, closed POD, temporary/off-site vaccination clinics + potential for mobile clinics People at higher risk of severe COVID-19 illness — potential for mobile clinics to long-term care facilities (LTCFs)	

### Availability Assumptions

Candidate	Vaccine availability under EUA by			Notes
	End of Oct 2020	End of Nov 2020	End of Dec 2020	
Vaccine B	~1M doses	~10M doses	~15M doses	Central distributor capacity required (-20 °C)

### Distribution, Storage, Handling, and Administration Assumptions

Vaccine B	
<b>SHIPMENT</b> 2 separately shipped components <ol style="list-style-type: none"> <li>Vaccine               <ul style="list-style-type: none"> <li>To central distributor (at -20 °C)</li> <li>Multidose vials (10 doses/vial)</li> </ul> </li> <li>Ancillary supply kits               <ul style="list-style-type: none"> <li>Direct to site from USG (at room temperature)</li> </ul> </li> </ol>	<b>ON-SITE VACCINE STORAGE</b> Frozen (-20 °C) <ul style="list-style-type: none"> <li>Storage in shipping container OK</li> </ul> Refrigerated (2–8 °C) <ul style="list-style-type: none"> <li>Must use within 14 days</li> </ul> Room temperature <ul style="list-style-type: none"> <li>Must use within 6 hours (discard any unused vaccine after 6 hours)</li> </ul>
<b>ORDERS</b> Central distribution capacity required <ul style="list-style-type: none"> <li>Required by Dec 2020</li> <li>Maintained at -20 °C</li> </ul>	<b>ADMINISTRATION</b> 2-dose series (28 days between doses) <ul style="list-style-type: none"> <li>No on-site mixing required</li> <li>Administer by IM injection</li> </ul>
<b>INITIAL POPULATIONS OF FOCUS AND ANTICIPATED VACCINE ADMINISTRATION SITES</b> Healthcare personnel — healthcare clinics + healthcare occupational health clinics + public health, closed POD, temporary/off-site vaccination clinics + mobile clinics Other essential workers (specifics TBA) — occupational health + hospital clinics + public health, closed POD, temporary/off-site vaccination clinics People at higher risk of severe COVID-19 illness (e.g., LTCF residents) — commercial pharmacy partners + mobile clinics	

[https://www.cdc.gov/vaccines/imz-managers/downloads/COVID-19-Vaccination-Program-Interim\\_Playbook.pdf](https://www.cdc.gov/vaccines/imz-managers/downloads/COVID-19-Vaccination-Program-Interim_Playbook.pdf)

10

# Vaccine A Storage Assumptions

## Availability Assumptions

Vaccine availability under EUA by			
Candidate	End of Oct 2020	End of Nov 2020	End of Dec 2020
Vaccine A	~2 million (M) doses	10M–20M doses	20M–30M doses
Notes			
Ultra-cold (-70 °C) storage requirements, for large sites only			

## Distribution, Storage, Handling, and Administration Assumptions

Vaccine A	
<b>SHIPMENT</b> <i>3 separately acquired components (mixed on site)</i> <ol style="list-style-type: none"> <li>Vaccine           <ul style="list-style-type: none"> <li>Direct to site from manufacturer (on dry ice)</li> <li>Multidose vials (5 doses/vial)</li> </ul> </li> <li>Diluent           <ul style="list-style-type: none"> <li>Direct to site from the US Government (USG) at room temperature</li> </ul> </li> <li>Ancillary supply kits (for administration and mixing)           <ul style="list-style-type: none"> <li>Direct to site from USG (at room temperature)</li> </ul> </li> </ol>	<b>ON-SITE VACCINE STORAGE</b> <i>Frozen (-70 °C ± 10 °C)</i> <ul style="list-style-type: none"> <li>Must be used/recharged within 10 days</li> <li>Storage in shipping container OK (replenish dry ice within 24 hours of receiving shipment and again 5 days later)</li> </ul> <i>Thawed but NOT reconstituted (2–8 °C)</i> <ul style="list-style-type: none"> <li>Must use within 5 days (discard unused doses after 5 days)</li> </ul> <i>Reconstituted (room temperature)</i> <ul style="list-style-type: none"> <li>Must use within 6 hours (discard any unused, reconstituted vaccine after 6 hours)</li> </ul>
<b>ORDERS</b> <i>Large quantities, to large administration sites only</i> <ul style="list-style-type: none"> <li>Minimum order: ~1,000 doses</li> <li>Maximum order: ~5,000 doses</li> </ul>	<b>ADMINISTRATION</b> <i>2-dose series (21 days between doses)</i> <ul style="list-style-type: none"> <li>On-site mixing required; reconstitute with diluent just prior to administration</li> <li>Administer by intramuscular (IM) injection</li> </ul>
<b>INITIAL POPULATIONS OF FOCUS AND ANTICIPATED VACCINE ADMINISTRATION SITES</b> <i>Healthcare personnel</i> — public health, closed point of dispensing (POD), temporary/off-site vaccination clinics + potential for mobile clinics <i>Other essential workers</i> — public health, closed POD, temporary/off-site vaccination clinics + potential for mobile clinics <i>People at higher risk of severe COVID-19 illness</i> — potential for mobile clinics to long-term care facilities (LTCFs)	

[https://www.cdc.gov/vaccines/imz-managers/downloads/COVID-19-Vaccination-Program-Interim\\_Playbook.pdf](https://www.cdc.gov/vaccines/imz-managers/downloads/COVID-19-Vaccination-Program-Interim_Playbook.pdf)

11

# Vaccine A

## Vaccine A Stability:

Ultra-Low Temperature (ULT) Storage: 6 Months

Thawed but not reconstituted(2-8 C): 5 Days

Reconstituted (Room Temperature): 6 Hours

## Diluent Stability:

Stable at room temperature

## Other considerations:

- Vaccine A will be provided in multidose vials
- Vaccine A must be thawed (30 minutes prior to use)
- Vaccine A must be mixed with diluent
- 2<sup>nd</sup> dose at 21 days

12

## ULT SHIPPING CONTAINERS

- ❖ Will hold 1000 doses of vaccine
- ❖ May be opened a maximum of 2x per day
- ❖ Require replenishment with dry ice pellets in 24 hours of receipt and again in 5 days
- ❖ May be replenished with 23 kg (50.6 lb) of dry ice to extend shelf life
- ❖ Re-usable
  - ❖ Return is required within 10-13 days.
- ❖ Shipping container dimensions 2'x2'x1.5'
- ❖ Shipping container weight 70-90lbs.

13

## ULT SHIPPING CONTAINERS

### Training Considerations:

- Dry ice handling and PPE requirements
- Monitoring of temperature probes
- Procedure for ensuring container is not opened more than 2x/day
- Return procedures for shipping containers

14

DRY ICE SUBLIMATES  
PRODUCING CARBON  
DIOXIDE


### Storage Considerations:

- If dry ice is held in a small enclosed environment open the door for a few minutes prior to walking in.
- If transporting dry ice, make sure vehicle windows are cracked open to ensure ventilation.

15

#### New Lows

Some of the vaccines being developed for Covid-19 might require colder temperatures for transport than typical vaccines. A comparison, in degrees Celsius:



<https://www.wsj.com/articles/covid-19-vaccine-race-turns-deep-freezers-into-a-hot-commodity-11599217201>

### Do I need to prepare for Ultra-Cold Chain Vaccines?

- All pharmacies should stay up to date on information from the CDC and HHS regarding potential ultra-cold chain storage requirements
- Pharmacies should plan for ultra-cold chain logistics even if it is unlikely their location will receive ultra-cold chain vaccine

16



# SUPPLY CONSIDERATIONS FOR ULT VACCINE

17



DRY ICE  
PELLETS

18

## PLASTIC ICE SCOOP



19

## Insulated Gloves




20

## Safety Glasses



21


## ULTRA LOW TEMPERATURE DATA LOGGER WITH AUDIBLE ALARM



22

### New Lows

Some of the vaccines being developed for Covid-19 might require colder temperatures for transport than typical vaccines. A comparison, in degrees Celsius:



<https://www.wsj.com/articles/covid-19-vaccine-race-turns-deep-freezers-into-a-hot-commodity-11599217201>

## Do I need to prepare for Ultra-Cold Chain Vaccines?

- All pharmacies should stay up to date on information from the CDC and HHS regarding potential ultra-cold chain storage requirements
- Pharmacies should plan for ultra-cold chain logistics even if it is unlikely their location will receive ultra-cold chain vaccine

23

## COVID-19 VACCINE PROVIDER ENROLLMENT

### STEPS TO TAKE IMMEDIATELY

- If you are not enrolled in NMSIIS, enroll now. Contact the NMSIIS help desk today.
- If you are enrolled but not a data exchange provider, contact NMSIIS help desk today.

### STEPS TO TAKE IN THE FUTURE

- Mandatory enrollment forms are being piloted. Stay tuned....
  - Enroll in the federal COVID-19 Vaccination Program through the New Mexico Immunization Program
  - Sign and agree to the conditions in the CDC COVID-19 Vaccination Program Provider Agreement.

**Immunization & NMSIIS Help Desk**  
1-833-882-6454

24

## NMSIIS DATA EXCHANGE INFORMATION

### **NMSIIS Data Exchange Locations:**

<https://www.nmhealth.org/publication/view/general/5490/>

### **How to Become a Data Exchange Provider:**

Contact the NMSIIS Help Desk and ask to become a Data Exchange Provider

***Immunization & NMSIIS Help Desk***

***1-833-882-6454***

25

## FEDERAL COVID-19 VACCINE PROVIDER REQUIREMENTS

- Administer COVID-19 vaccine in accordance with ACIP recommendations.
- Within 24 hours of administering a dose of COVID-19 vaccine and adjuvant (if applicable), record in the vaccine recipient's record and report required information to the relevant state, local, or territorial public health authority.
- Not sell or seek reimbursement for COVID-19 Vaccine and any adjuvant, syringes, needles, or other constituent products and ancillary supplies provided by the federal government.
- Administer COVID-19 vaccine regardless of the vaccine recipient's ability to pay.
- Provide an Emergency Use Authorization (EUA) fact sheet or vaccine information statement (VIS), as applicable, to each vaccine recipient/parent/legal representative prior to vaccination.
- Comply with CDC requirements for vaccine management, including storage and handling, temperature monitoring at all times, complying with jurisdiction's instructions for dealing with temperature excursions, and monitoring expiration dates.

26

## FEDERAL COVID-19 VACCINE PROVIDER REQUIREMENTS


- Report COVID-19 vaccines and adjuvants that were unused, spoiled, expired, or wasted as required by the jurisdiction's immunization program.
- Comply with federal instruction regarding disposal of unused COVID-19 vaccine and adjuvant.
- Report adverse events to the Vaccine Adverse Event Reporting System (VAERS).
- Provide a completed COVID-19 vaccination record card to every vaccine recipient/parent/legal representative.
- Comply with the U.S. Food and Drug Administration's requirements, including EUA-related requirements, if applicable. Providers must also administer COVID-19 vaccine in compliance with all applicable state and territorial vaccine laws.

27

## Allocation

The federal government will determine the amount of COVID-19 vaccine designated for each jurisdiction.

New Mexico Immunization program will be responsible for managing and approving orders from enrolled providers within the state



\*Planning should consider that there may be initial age restrictions for vaccine products.

\*\*See Section 4: Critical Populations for information on Phase 1 subset and other critical population groups.

28

## Two Supply Routes

### FEDERAL GOVERNMENT

- IHS
  - Tribal governments have option of obtaining through IHS or the state
- VA
- 16 PARTNER PHARMACIES
  - 85% of pharmacies in the US
  - Retail chains with 200+ stores
  - 3 largest independent pharmacy networks
  - Federal government will be releasing partner names upon finalization of contracts

### STATE GOVERNMENT

- All facilities not supplied directly by the federal government

29

## Vaccine Ordering & Inventory Tracking

Minimum order size: 100 doses per order

- Some ultra-cold vaccine (if authorized for use or approved) may be shipped directly from the manufacturer in larger quantities (minimum of 1000 doses).

### Federal Government Supply Chain

- Vaccine allocation and centralized distribution will utilize HHS's Vaccine Tracking System (VTrckS)
- <https://www.cdc.gov/vaccines/programs/vtrcks/index.html>
- IHS, private partners, and VA will receive training.

### State Government Supply Chain

- Ordering will occur through NMSIIS.

30

## Ancillary Supply Kits

Will come automatically with vaccine order. Each kit will contain supplies to administer 100 doses of vaccine, including:

- Needles, 105 per kit (various sizes for the population served by the ordering vaccination provider)
- Syringes, 105 per kit
- Alcohol prep pads, 210 per kit
- 4 surgical masks and 2 face shields for vaccinators, per kit
- COVID-19 vaccination record cards for vaccine recipients, 100 per kit
- For COVID-19 vaccines that require reconstitution with diluent or mixing with adjuvant at the point of administration, mixing kits with syringes, needles, and other needed supplies will also be included.

Do NOT include:

- Sharps containers, gloves, bandages or other PPE.


31

## COVID-19 VACCINES & ANCILLARY SUPPLY KITS

WILL BE SUPPLIED AT **NO COST** TO  
PROVIDERS

32





## Ordering & Distribution

33



### Turn-Around Time

COVID-19 vaccine will be shipped direct to vaccination provider sites within 48 hours of order approval.

Ancillary supply kits (and diluent, if applicable) will ship separately from vaccine but should arrive before or on the same day as vaccine.

Some vaccine may be distributed to health department for further distribution to administration sites

34

## Inventory Tracking

- Inventory reporting will be required
  - Inventory frequency is unknown at this time
  - At a minimum inventory reporting will be with each vaccine order
  - Federal partners may have daily reporting requirements
- CDC is still releasing inventory reporting requirements

35

## Vaccine Billing

- CDC will allow administration fees to be billed to insurances.
  - Vaccine providers MUST administer COVID-19 vaccine regardless of the vaccine recipient's ability to pay.
- CDC will share more information about reimbursement claims for administration fees as it becomes available.

36

## CARES Act Provider Relief Fund

The Provider Relief Funds supports American families, workers, and the heroic healthcare providers in the battle against the COVID-19 outbreak. HHS is distributing \$175 billion to hospitals and healthcare providers on the front lines of the coronavirus response.



## POSSIBLE REIMBURSEMENT FOR VACCINES ADMINISTERED TO THE UNINSURED

37




Reporting will be required by the CDC **WITHIN 24 HOURS** of administration

## Vaccine Administration Reporting

- Facilities **WITH** data exchange on NMSIIS can report administration in their EHR **alone**.
- Facilities **WITHOUT** data exchange on NMSIIS must report administration on their EHR and on NMSIIS.

State law requires ALL providers to report vaccine administration in NMSIIS regardless of their supply chain

38



## When does Pharmacy Come In?

During Phase 1, administration sites may be more limited to settings that can optimize reaching the target population while meeting the early requirements for storage and handling of vaccine product.

During Phase 2, an expanded administration network would, for instance, likely include adult and pediatric healthcare providers and pharmacies. These considerations will be part of planning done by the jurisdictions discussed in the Distribution section.

\*Planning should consider that there may be initial age restrictions for vaccine products.  
\*\*See Section 4: Critical Populations for information on Phase 1 subset and other critical population groups.

39

## Pharmacy & Long-Term Care



40

## LTCF COVID-19 VACCINE

## FEDERAL PHARMACY PARTNERSHIP

- CDC partnership with CVS and Walgreens Pharmacies
- COVID-19 vaccination clinics at long-term care facilities
- Federal pharmacy partner will conduct end to end management
  - Scheduling, Vaccine ordering, Vaccine reporting to states/CDC
  - Will provide facility a vaccine administration report for their records.
- All services will be provided free of charge to the patient and facility
- The focus will be for residents. However, any unvaccinated facility staff can receive a vaccine during these clinics
- Neither CMS nor the state will mandate COVID-19 vaccine. Patient and staff vaccination is voluntary.
- Enrollment is through a national survey running through November 2<sup>nd</sup>.
- Facilities may opt-out and choose to administer vaccine utilizing their own staff or a local pharmacy partner

41

## When does Pharmacy Come In?

Phase 1	
<b><u>Phase 1-A:</u></b>	<ul style="list-style-type: none"> <li>• Paid and unpaid persons serving in healthcare settings who have the potential for direct or indirect exposure to patients or infectious materials and are unable to work from home.</li> </ul>
<b><u>Phase 1-B:</u></b>	<ul style="list-style-type: none"> <li>• Other essential workers</li> <li>• People at higher risk of severe COVID-19 illness, including people 65 years of age and older</li> </ul>

### PHASE 1-OUTREACH CLINICS

42

## When will more information be available?

The state is receiving new information daily from the CDC and HHS. We will continue to update you as more information becomes available.

The information in this slide set may change. Please continue to stay up-to-date on available information.

43

Please start logistics planning

Please sign up as a COVID-19 provider when the form is released


Please participate in outreach clinics



44




45




[https://www.cdc.gov/vaccines/imz-managers/downloads/COVID-19-Vaccination-Program-Interim\\_Playbook.pdf](https://www.cdc.gov/vaccines/imz-managers/downloads/COVID-19-Vaccination-Program-Interim_Playbook.pdf)

46



[hhs.gov/sites/default/files/strategy-for-distributing-covid-19-vaccine.pdf](https://hhs.gov/sites/default/files/strategy-for-distributing-covid-19-vaccine.pdf)

47



<https://www.nmhealth.org/about/phd/idb/imp/>

48